Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis-Reference-Cited by-同舟云学术

Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis

Published:2016-03-24 Issue:5 Volume:12 Page:509-521
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Zuur Marlanka A.¹,Bolhuis Mathieu S.¹,Anthony Richard²,den Hertog Alice²,van der Laan Tridia³,Wilffert Bob¹⁴,de Lange Wiel⁵⁶,van Soolingen Dick³⁷,Alffenaar Jan-Willem C.¹

Affiliation:

1. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

2. Royal Tropical Institute (KIT), KIT Biomedical Research, Amsterdam, The Netherlands

3. National Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

4. Department of Pharmacy, section Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands

5. University of Groningen, University Medical Center Groningen, Tuberculosis Centre Beatrixoord, Haren, The Netherlands

6. Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

7. Departments of Pulmonary Diseases and Medical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

Publisher

Informa Healthcare

Subject

Pharmacology,Toxicology,General Medicine

Link

https://tandfonline.com/doi/pdf/10.1517/17425255.2016.1162785

Reference107 articles.

1. Global tuberculosis report 2015 [Internet]. World Health Organization; 2015. Available from: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1; http://www.who.int/en/:

2. Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000–2009

3. Overview of pharmacokinetics [Internet]. 2014. Available from: http://www.msdmanuals.com/professional/clinical-pharmacology/pharmacokinetics/overview-of-pharmacokinetics.

4. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetic model of rifampicin for personalized tuberculosis pharmacotherapy: Effects of SLCO1B1 polymorphisms on drug exposure;International Journal of Antimicrobial Agents;2024-02

2. Development and Validation of a UPLC-MS/MS Method for Therapeutic Drug Monitoring, Pharmacokinetic and Stability Studies of First-Line Antituberculosis Drugs in Urine;Molecules;2024-01-09

3. Effect of Bedaquiline and Delamanid Pharmacokinetics on Sputum Culture Conversion and Adverse Events in Drug-Resistant Tuberculosis;Therapeutic Drug Monitoring;2024-01-01

4. A Single-Run HPLC–MS Multiplex Assay for Therapeutic Drug Monitoring of Relevant First- and Second-Line Antibiotics in the Treatment of Drug-Resistant Tuberculosis;Pharmaceutics;2023-10-27

5. New approach to rifampicin stability and first-line anti-tubercular drug pharmacokinetics by UPLC-MS/MS;Journal of Pharmaceutical and Biomedical Analysis;2023-10